Latanoprost and Melphalan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Latanoprost (latanoprost) and Melphalan (melphalan). Common drug interactions include cardiac failure congestive among females and pneumonia among males.

The phase IV clinical study analyzes what interactions people have when they take Latanoprost and Melphalan. It is created by eHealthMe based on reports of 27 people who take the same drugs from the FDA, and is updated regularly.

What is Latanoprost?

Latanoprost has active ingredients of latanoprost. It is often used in glaucoma. eHealthMe is studying from 33,250 Latanoprost users. Check the latest studies of Latanoprost.

What is Melphalan?

Melphalan has active ingredients of melphalan. eHealthMe is studying from 20,052 Melphalan users. Check the latest studies of Melphalan.

On Aug, 05, 2026

27 people who take Latanoprost and Melphalan together, and have interactions are studied.

Latanoprost and Melphalan drug interactions.

What are the common drug interactions of Latanoprost and Melphalan, by gender? *:

female:

Cardiac failure congestive
Constipation
Fluid overload (too much fluid in the blood)
Hepatic enzyme increased
Ischaemic stroke (stroke; caused by an interruption in the flow of blood to the brain)
Diastolic dysfunction
Leukopenia (less number of white blood cells in blood)
Neutropenia (an abnormally low number of neutrophils)
Thrombocytopenia (decrease of platelets in blood)
White blood cell count decreased

male:

Pneumonia
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Full blood count decreased
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
Overdose
Renal failure (kidney dysfunction)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)

What are the common drug interactions of Latanoprost and Melphalan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Atrioventricular block second degree (heart block second degree)

60+:

Adenocarcinoma pancreas (cancer of pancreas)
Pneumonia viral
Leukopenia (less number of white blood cells in blood)
Neutropenia (an abnormally low number of neutrophils)
Thrombocytopenia (decrease of platelets in blood)
White blood cell count decreased
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Full blood count decreased
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
Overdose

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 18 people, 66.67%
Dry Eyes (lack of adequate tears): 12 people, 44.44%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 11 people, 40.74%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 11 people, 40.74%
Hypokalemia (low potassium): 11 people, 40.74%
High Blood Pressure: 8 people, 29.63%
Diabetes: 6 people, 22.22%
Back Pain: 6 people, 22.22%
Constipation: 6 people, 22.22%
Abdominal Pain Upper: 6 people, 22.22%

* Approximation only. Some reports may have incomplete information.

Do you take Latanoprost and Melphalan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously